Mitogen-activated protein kinase inhibitors

Davis, T., Baird, D. M., Haughton, M. F., Jones, C. J., and Kipling, D. (2005). Prevention of accelerated cell aging in Werner syndrome using a p38 mitogen-activated protein kinase inhibitor. J. Gerontol. A Biol. Sci. Med. Sci. 60,1386-1393. 

Montero, M., Lobaton, C. D., Moreno, A., and Alvarez, J., 2002, A novel regulatory mechanism of the mitochondrial Ca2+ uniporter revealed by the p38 mitogen-activated protein kinase inhibitor SB202190, FASEB J. 16, pp. 1955-1957... 

Lin Z, Crockett DK, Jenson SD, Lim MS, Elenitoba-Johnson KS. Quantitative proteomic and transcriptional analysis of the response to the p38 mitogen-activated protein kinase inhibitor SB203580 in transformed follicular lymphoma cells. Mol Cell Proteomics 2004 3(8) 820-833. 

Trask, O.J., Jr. et al. 2006. Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the Array Scan 3.1 imaging platform. Meth. Enzymol. 414, 419-439. 

Barone FC, Irving FA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey Ml, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, Smith BR, Adtuns JL, Parsons AA (2001) SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 296 312-321... 

Branger J, et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 2002 168 4070-4077. 

Parasrampuria, D.A. de Boer, P. Desai-Krieger, D. Chow, AT. Jones, C.R. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor a first-in-human study. J. Clin. Pharmacol. 2003, 43 (4), 406-413. 

Xiao, Z., Varma, S., Xiao, Y.-D. andTropsha, A. (2004) Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods. J. Mol. Graph. Model, 23, 129-138. 

Lee,J.C.,Kassis,S.,Kumar,S.,Badger,A.,and Adams, J.L. (1999) p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol. Ther. 82, 389-97. 

A series of novel 1,6-naphtyridine derivatives were prepared as potential inhibitors of human topoisomerase I (2003JMC2254), farnesyltransferase inhibitors (2003USP2003199544), p38 mitogen-activated protein kinase inhibitors (2003MI7), SYK kinase inhibitors (2003PIAW02003057695) and spleen tyrosine kinase inhibitors (2003MI8). 

Biihler S, Goettert M, Schollmeyer D, Albrecht W, Laufer SA. Chiral sulfoxides as metabolites of 2-thioimidazole-based p38r mitogen-activated protein kinase inhibitors enantiose-lective synthesis and biological evaluation. J. Med. Chem. 2011 54 3283-3297. 

---